Promethazine w. Codeine CV
Generic Name and Formulations:
Codeine phosphate 10mg, promethazine HCl 6.25mg; per 5mL; syrup; contains alcohol 7%.
Various generic manufacturers
Indications for Promethazine w. Codeine:
Cough and upper respiratory symptoms associated with allergy or common cold.
Use lowest effective dose for shortest duration. Use accurate measuring device. ≥12yrs: 5mL every 4–6hrs; max 30mL/24hrs.
<12yrs: see Contraindications.
Children <12yrs. Post-op management in children <18yrs following tonsillectomy and/or adenoidectomy. Coma. Lower respiratory disorders. Asthma.
Risk of life-threatening respiratory depression and death related to ultra-rapid metabolizers of codeine (esp. in children for post-tonsillectomy and/or adenoidectomy pain). Avoid in adolescents 12–18yrs with conditions associated with hypoventilation (eg, post-op status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, concomitant drugs that cause respiratory depression). Head injury, intracranial lesions or pre-existing increase in intracranial pressure. Avoid in chronic respiratory disease, acute febrile illness with productive cough, compromised respiratory function (eg, COPD, sleep apnea). Discontinue if neuroleptic malignant syndrome (NMS) occurs. Seizure disorders. Bone marrow depression. Acute abdomen. Fever. Hypothyroidism. Addison's disease. Ulcerative colitis. Prostatic hypertrophy. Recent GI or urinary tract surgery. Narrow-angle glaucoma. Stenosing peptic ulcer. Pyloroduodenal or bladder-neck obstruction. Dehydration. Avoid prolonged sun exposure. Severe hepatic or renal impairment. Ultra-rapid metabolizers (due to CYP2D6 polymorphism): avoid. Atopic children. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antitussive + antihistamine.
Increased risk of respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, opioids, antihistamines, antipsychotics, anxiolytics, alcohol); avoid. Concomitant epinephrine: not recommended. Increased risk of NMS with concomitant antipsychotics. Caution with anticholinergics. Increased extrapyramidal effects with MAOIs. Concomitant narcotics, local anesthetics: may lower seizure threshold. May alter hCG pregnancy test and glucose tolerance test results.
Drowsiness, CNS or respiratory depression, constipation, anticholinergic effects, orthostatic hypotension, photosensitivity, paradoxical excitement, changes in blood pressure, convulsions, jaundice, blood dyscrasias.
Formerly known under the brand name Phenergan with Codeine.
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- OnabotulinumtoxinA May Be Effective for Chronic Migraine With Medication Overuse
- FDA Outlines Plan for Increasing Nonprescription Drug Availability
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Hypoesthesia for Touch and Joint Position Linked to Chronic Pain in MS
- New Laws Are Needed to Protect Health Data Shared Online